Search | IOVS | ARVO Journals

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

A novel treatment of OPA1 splice defects by U1 snRNA adaptions in a DOA mouse model and patient-derived cells

Christoph Jüschke; Sebastian Swirski; Thomas Klopstock klopstock; Bernd Wissinger; John Per Neidhardt

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1916. doi:

ARVO Annual Meeting Abstract June 2020

Bilateral Visual Improvement with Unilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)

Patrick Yu-Wai-Man; Nancy J Newman; Valerio Carelli; Valerie Biousse; Alfredo A. Sadun; Mark L Moster; Catherine Vignal-Clermont; Robert C Sergott; Thomas Klopstock klopstock; Laure Blouin; Magali Taiel; Pierre Burguière; Caroline Chevalier; Barrett Katz; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):5181. doi:

ARVO Annual Meeting Abstract July 2019

Childhood onset Leber's Hereditary Optic Neuropathy (LHON) treated with Idebenone compared to an age-related untreated patient cohort

Susanna Friederike Koenig; Siegfried Priglinger; Guenther Rudolph; Felice Lob; Bettina Livonius; Claudia Catarino; Thomas Klopstock; Claudia Priglinger

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1832. doi:

ARVO Annual Meeting Abstract July 2019

rAAV2/2- ND4 for the Treatment of Leber Hereditary Optic Neuropathy (LHON): 72-Week Data from the REVERSE Phase III Clinical Trial

Patrick Yu-Wai-Man; Mark Moster; Alfredo A Sadun; Thomas Klopstock; Catherine Vignal-Clermont; Nancy J Newman; Robert C Sergott; Valerio Carelli; Caroline Chevalier; Laure Blouin; Magali Taiel; Barrett Katz; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4806. doi:

ARVO Annual Meeting Abstract July 2018

Maintenance of Idebenone Treatment after an Initial Visual Recovery Results in Continued Improvement in LHON Patients

Xavier Lloria; Magda Silva; Guenther Rudolph; Felice Lob; Bettina von Livonius; Claudia Catarino; Thomas Klopstock

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3361. doi:

ARVO Annual Meeting Abstract July 2018

Natural History Data (NHD) In A Cohort Of 383 Patients with Leber’s Hereditary Optic Neuropathy (LHON). Results From An International Retrospective Case Record Survey (CRS)

Magda Silva; Xavier Lloria; Claudia Catarino; Thomas Klopstock; Jose A. Sahel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3362. doi:

ARVO Annual Meeting Abstract June 2017

Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE Clinical Gene Therapy Trials

Patrick Yu-Wai-Man; Nancy J Newman; Robert Sergott; Molly Scannell Bryan; Valerio Carelli; Thomas Klopstock; Mark Moster; Alfredo A. Sadun; Jose Alain Sahel; Catherine Vignal; Scott Uretsky

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3865. doi:

ARVO Annual Meeting Abstract September 2016

Treatment of visual impairment in patients with Leber’s Hereditary Optic Neuropathy (LHON) using Idebenone (Raxone®)

Shabir Hasham; Guenther Metz; Claudia Catarino; Thomas Klopstock

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5085. doi:

ARVO Annual Meeting Abstract April 2014

Clinical experience with Idebenone (Raxone®) in the treatment of patients with Leber’s Hereditary Optic Neuropathy (LHON)

Guenther Metz; Constanze Gallenmueller; Thomas Meier; Thomas Klopstock; Physicians participating in the Raxone Expanded Access Program

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6206. doi:

Clinical and Epidemiologic Research July 2009

Quality of Life in Patients with Leber Hereditary Optic Neuropathy

PDF

Matthew Anthony Kirkman; Alex Korsten; Miriam Leonhardt; Konstantin Dimitriadis; Ireneaus F. De Coo; Thomas Klopstock; Philip G. Griffiths; Gavin Hudson; Patrick F. Chinnery; Patrick Yu-Wai-Man
TAGS: optic atrophy, hereditary, leber, quality of life, visual impairment
Invest. Ophthalmol. Vis. Sci.. 2009; 50(7):3112-3115. doi: https://doi.org/10.1167/iovs.08-3166

Advertisement